All In Biotech

Investigational drug · Phase 3

QL1604

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small-cell Lung Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

7

Any phase or sponsor naming "QL1604"

First trial start

2025

Feb 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "QL1604", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Small-cell Lung Cancer

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "QL1604" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Small-cell Lung Cancer

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • ZG006Phase 38 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor

  • GocatamigHPN328, MK-6070Phase 34 trials

    Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer

  • ZL-1310Phase 33 trials

    Zai Lab (Shanghai) Co., Ltd. · Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma

  • BL-M14D1Phase 32 trials

    SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma

  • IparomlimabPhase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

  • TuvonralimabPhase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

  • SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.